HCS Pharma

HCS Pharma

Created using Figma
HCS Pharma shares should be listed on the Frankfurt stock exchange in the next six months. The company is launching a pre-IPO on the European Digital Asset Exchange (EDSX) that will allow investors to buy shares with a 20% discount on the final listing price.

HCS Pharma has already raised more than €2 million with private sales and has recently opened the public sales: https://www.edsx.ch/projects/hcs-pharma

The goal is to raise €7 million to strengthen its position as a developer of regenerative medicine and cellular therapy.
8 Apr 2022
8 Jun 2022
100% lengkap
$209 720 767
28% tujuan lengkap
Tujuan 734 022 685.00 USD
past
  • 1 HCS
    =
    500 USD
Detail Token
Jantung
HCS
Total pasokan
€ 7 million
Distribusi Token
European Digital Asset Exchange | https://www.edsx.ch/projects/hcs-pharma
Mata Uang yang Diterima
BTC, CHF, EUR, USDT, DOLLAR
Kontribusi Min
500
TOKEN
Detail Perusahaan
Nama Perusahaan Terdaftar
HCS Pharma SAS
Negara Terdaftar
France
Perusahaan Didirikan
Jan 1, 2014
Struktur Bonus
20% discount offered on final share price
detil tambahan
Peron
eos
Kategori
Peron

Tentang HCS Pharma

HCS Pharma is a biotechnology company focused on in vitro R&D, specializing in high content (HCA) and high throughput (HCS) cell imaging screening. HCS Pharma sells products based on BIOMIMESYS® technology, and develops its own 3D cellular models in its proprietary BIOMIMESYS® extracellular matrix. BIOMIMESYS® 3D culture technology faithfully reproduces the natural microenvironment of cells in 3D, to ensure more predictive results from in vitro studies, to reduce the time and cost of R&D, and animal testing in pharmaceutical, nutraceutical and cosmetic companies. BIOMIMESYS® technology is also requested to be used in cell therapy and regenerative medicine, allowing HCS Pharma to become the leader in all biotechnology industries in the next 5 years. 

fitur

BIOMIMESYS® is a unique groundbreaking 3D cell culture technology which associates the behavior of a solid scaffold and of a hydrogel which provide a cell culture microenvironment reproducing all aspects of human tissues, including matrix architecture, cellular organization, cell-cell and cell-matrix interactions. 

Depending on the organ, extracellular matrix components may vary as well their proportions, allowing a more or less dense and compact cellular environment (different Elastic Modulus, porosity). 

BIOMIMESYS® matrices are made of Hyaluronic Acid (HA), the main glycosaminoglycan (GAG) of the ECM, collagens and adhesion proteins. Our patented manufacturing process allow preserving the natural properties of HA and therefore synthesizing proprietary Hydroscaffold™. 

Info Teknis

HCS Pharma owns 2 cell culture labs and one automation lab equipped with a robotic platform named HAPIx, including 2 confocal HCS systems, ImageXpress micro confocal systems from Molecular Devices, and a ImageXpress micro XLS also from Molecular Devices and a chemical lab for BIOMIMESYS® production.

% name% Roadmap

  • 18 months

  • - 6 months: Development of a sales force in the different countries in Europe.

    - 1 year: New production line set up + Development of a technical support center in Taiwan + fundraising and/or IPO project.

    - 18 months: Presence in the US.
  • 10 Years

  • - In 3 years, from patient cells, we will be able to recreate small diseased organs to test molecules and find the most suitable therapy for personalized medicine.

    - In 5 years, we will be able to find much more effective clinical drug candidates and therefore ultimately treat patients with cancer, Parkinson's disease, or Alzheimer's.

    - In 10 years, we will be able to recreate complete organs for organ transplantation. And from animal cells, we will be able to recreate muscle and therefore cultured meat.

HCS Pharma Tim

Diverifikasi 25%

Perhatian. Ada risiko bahwa anggota yang tidak diverifikasi sebenarnya bukan anggota tim

Nathalie Maubon
CEO
diverifikasi
Elodie Vandenhaute
Project Manager
tidak diverifikasi
Zied Souguir
Biomaterial Department Manager
tidak diverifikasi
Gregory Maubon
Chief Development Officer and IA Project Leader
tidak diverifikasi

Penasihat

Diverifikasi 100%

Mauro Andriotto
Advisor
diverifikasi

HCS Pharma Wawancara

Mauro Andriotto
As a team member, сan you tell us about your role in the ICO project?
I am the CEO of the European Digital Assets Exchange where HCS Pharma is listed on the primary market.
What do you think about idea?
It's an amazing company selected by the European Commission between the most 50 most disruptive biotech in Europe and there is the plan to list the company on the Frankfurt Stock Exchange by the end of the year.
Nathalie Maubon
As a team member, сan you tell us about your role in the ICO project?
We have decided to go public before the end of the year by a Reverse Take Over (RTO) with a pre-IPO fund-raising such as STO. This STO in pre-IPO will give the possibility to crypto investors to be onboarded.
What do you think about idea?
This STO coupled with the STO makes it possible to rally virtual currency investors with the traditional market.

HCS Pharma Berita terakhir

  • Karena mungkin ada perbedaan waktu dalam pembaruan informasi, informasi akurat tentang setiap proyek ICO harus diverifikasi melalui situs resminya atau saluran komunikasi lainnya.
  • Informasi ini bukan saran atau saran tentang berinvestasi dalam pendanaan ICO. Silakan teliti sendiri informasi yang relevan dan putuskan partisipasi ICO.
  • Jika Anda merasa ada masalah atau masalah yang harus diperbaiki pada konten ini, atau jika Anda ingin mengirimkan proyek ICO Anda sendiri untuk dicantumkan, Harap email kami.
Silahkan baca disclaimer dan risk warning. Tampilkan disclaimer dan risk warning.